|Tuesday, 29 November 2016, 08:00 HKT/SGT|
|- Seven clinical trials across the world|
- More than 2/3 of STS patients recruited in the "act.in.sarc" Phase II/III trial
- Phase I/II prostate cancer trial now recruiting in the U.S.
Paris, France and Cambridge, Massachusetts, USA, Nov 29, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides an update on the global development of its lead product, NBTXR3, across all indications.
NBTXR3 is a first-in-class radio-enhancer nanoparticle designed for direct injection into cancerous tumors. NBTXR3 has the potential to improve radiotherapy efficacy by destroying locally advanced tumors more efficiently. It has been engineered to increase the local absorption of the radiotherapy dose and thereby increasing the efficacy of radiotherapy with the benefit of not increasing toxicity or causing damage to surrounding healthy tissues.
Elsa BORGHI, CMO of Nanobiotix said: "We made significant progress this year with the global clinical development of NBTXR3 across seven clinical trials and we are looking forward to potentially obtain a CE mark in 2017. Our filing was based on the scale and significance of the results already seen. The clinical and regulatory progress sets the stage for 2017, as we are getting closer to establishing NBTXR3 in combination with radiotherapy as a new treatment modality for patients suffering from solid cancers."
Global development of NBTXR3
The Company currently has seven ongoing clinical trials across the world. Overall 15 countries with 54 clinical centers and more than 300 physicians are involved in Nanobiotix's clinical trials.
Image 1: https://www.acnnewswire.com/topimg/Low_nanobiotix1611291.jpg
Clinical development of NBTXR3 by indication
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region.
Highlights of clinical news:
- 115 patients have been randomized and 153 have signed the informed consent in the STS pivotal clinical trial. The target of 104 patients needed for the interim readout has been reached. A total of 156 STS evaluable patients is expected in the "act.in.sarc" Phase II/III trial (www.actinsarc.com).
- The Company expects to release the conclusion of the interim analysis conducted by an independent committee of experts in the coming months. This analysis will be performed four months after the 104th patient has been randomized (time to complete treatment plus readout).
- PharmaEngine has started a new clinical trial in Asia in October 2016 for head and neck patient's population receiving chemotherapy in combination with radiotherapy.
- A Phase I/II prostate cancer trial has been initiated in the US and now recruiting at Ronald Reagan UCLA Medical Center, Los Angeles and Thomas Jefferson University Hospital, Philadelphia. Dana Farber Cancer Institute, Boston should be joining the trial soon.
Status of ongoing clinical trials
Image 2: https://www.acnnewswire.com/topimg/Low_nanobiotix1611292.jpg
NBTXR3 first market authorization filing
The company filed for certification of NBTXR3 in August 2016 based on the current level of clinical and scientific evidence. LNE/G-MED, the French notified body, has given guidance that the review of results for a potential CE mark is expected in 2017.
Expansion into immuno-oncology
In November, the Company presented preclinical data at the annual meeting of the Society for Immunotherapy of Cancer (SITC), demonstrating that NBTXR3 actively stimulates the host immune system to attack tumor cells. Study results suggested NBTXR3's potential to transform the tumor into an in situ vaccine.
On top of the Company's core development activities, these findings could open new potential collaborations for NBTXR3 through combinations with other immuno-oncology drugs.
- Clinical Cancer Research - on NBTXR3 in Soft Tissue Sarcoma Phase I/II Trial: "First human study testing a new concept of radio enhancement using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas (STS)", published 6 October 2016. Sylvie Bonvalot, Cecile Le Pechoux, Thierry Debaere, Guy Kantor, Xavier Buy, Eberhard Stoeckle, Paul Sargos, Philippe Terrier, Jean-michel Coindre, Nathalie Lassau, Rafik AIT SARKOUH, Mikaela Dimitriu, Elsa Borghi, Laurent Levy, Eric Deutsch and Jean Charles Soria. 10.1158/1078-0432.CCR-16-1297
- Poster presented at SITC conference "Hafnium oxide nanoparticles, a radiation enhancer for in situ cancer vaccine", authored by Paris S., Pottier A., Levy L., and Lu B.
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
France - Springbok Consultants
+33 (0)6 71 58 00 34
EU Outside France - Instinctif Partners
Melanie Toyne Sewell
+44 (0) 207 457 2020
United States - The Ruth Group
Kirsten Thomas / Chris Hippolyte
+1 508-280-6592 / +1 646-536-7023
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorite des Marches Financiers) under number D.16-0732 on July 22, 2016 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NANOBIOTIX via Globenewswire
Nov 29, 2016 08:00 HKT/SGT
Topic: Research and development
Sectors: Science & Research, BioTech, HealthCare
From the Asia Corporate News Network
Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Mar 24, 2017 07:00 HKT/SGT|
NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma|
|Mar 7, 2017 15:50 HKT/SGT|
Nanobiotix to Present Preclinical Data on Nanoparticle Radioenhancer NBTXR3 at the AACR Annual Meeting 2017|
|Feb 7, 2017 16:30 HKT/SGT|
Nanobiotix Appoints Senior Executive from Pharmaceutical Industry, as Chief Operating Officer|
|Feb 1, 2017 08:00 HKT/SGT|
NANOBIOTIX: 2016 Review and 2017 Anticipated Milestones|
|Dec 15, 2016 08:00 HKT/SGT|
Nanobiotix Reports Positive Phase I/II Preliminary Data on Feasibility and Safety of NBTXR3 in Liver Cancers Trial|
|Nov 14, 2016 15:20 HKT/SGT|
Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as In Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting|
|Nov 7, 2016 17:00 HKT/SGT|
Nanobiotix' Partner PharmaEngine Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia|
|Oct 21, 2016 05:00 HKT/SGT|
Nanobiotix's Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia|
|Oct 4, 2016 08:00 HKT/SGT|
Nanobiotix Strengthens U.S. Leadership with Appointments of Head of U.S. Clinical Development and Director of Investor Relations|
|Sept 20, 2016 07:30 HKT/SGT|
Bpifrance Grants Nanobiotix a 2M EUR Interest-free Loan to Support Final Development Stage of Lead Product, NBTXR3|
|More news >>|